Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
For release content, please refer to the attachment....
-
For release content, please refer to the attachment....
-
The presentation will include an update on the following drugs: laquinimod, the company's oral MS drug for which it is in partnership with Teva Pharmaceutical Industries Ltd.; ANYARA,...
-
"We thank Maria for her strong engagement and valuable contribution to the development of Active Biotech. During her time as Board member, the company has developed into one of the most successful...
-
"Vi tackar Maria för hennes starka engagemang och värdefulla bidrag till uppbyggnaden av Active Biotech. Under hennes tid som styrelseledamot har bolaget utvecklats till ett av de mest...
-
Active Biotech (ACTI.ST). An interim analysis of the ongoing TASQ Phase I study shows a treatment effect for all evaluated prostate cancer patients. Phase II/III studies are planned to start in year...
-
Active Biotech (ACTI.ST). En interimsanalys av den pågående TASQ fas I-studien, visar en behandlingseffekt för samtliga utvärderade prostatacancerpatienter. Fas II/III studier planeras att inledas...
-
The presentation will include laquinimod, an oral immunmodulatory Multiple Sclerosis drug which is licensed to Teva Pharmaceutical Industries Ltd and recently successfully concluded a Phase IIb study;...
-
The article summarizes pre-clinical data regarding Active Biotech's project TASQ for the treatment of prostate cancer. The data verifies TASQ's anti-angiogenic activity i.e. inhibition of...
-
Artikeln sammanfattar prekliniska data för Active Biotechs projekt TASQ för behandling av prostatacancer. Resultaten bekräftar TASQs anti-angiogenicitet dvs. förmåga att hämma...